6 completed, 1 terminated, 1 unknown. 8 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow netarsudil: new trials by email Literature Review of netarsudil trials Research Report on netarsudil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| Next Generation Rocklatan AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 646 | 2024-09-04 | 2026-11-09 |
| A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Wills Eye | 80 | 2023-02-06 | 2024-07-30 |
| Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration Netarsudil, Placebo - Fuchs' Endothelial Dystrophy | Phase 2 / Phase 3 | Terminated | Price Vision Group | 19 | 2019-07-22 | 2023-02-06 |
| Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle - Ocular Hypertension, Open Angle Glaucoma | Phase 2 | Completed | Aerie Pharmaceuticals | 12 | 2016-07-01 | 2018-04-17 |
| Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02% - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Aerie Pharmaceuticals | 298 | 2014-01-01 | 2019-06-04 |
| Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005% - Ocular Hypertension, Open Angle Glaucoma | Phase 2 | Completed | Aerie Pharmaceuticals | 224 | 2012-11-01 | 2018-04-17 |
| Study of AR-13324 in Patients With Elevated Intraocular Pressure AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04% - Ocular Hypertension, Open Angle Glaucoma | Phase 2 | Completed | Aerie Pharmaceuticals | 85 | 2012-03-01 | 2018-04-18 |
Glaucoma, Open-Angle (5) · Ocular Hypertension (5) · Glaucoma (3) · Corneal Edema (1) · Fuchs' Endothelial Dystrophy (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Retinal Detachment (1) · Vitreoretinopathy, Proliferative (1)
Aerie Pharmaceuticals (4) · Alcon Research (1) · Price Vision Group (1) · University Hospital Dubrava (1) · Wills Eye (1)
United States (7) · Croatia (1)
Theresa Heah, MD (3) · Francis W Price, Jr, MD (1) · Jason Hsu, MD (1) · Josip Pavan, MD, PhD (1) · Nancy Ramirez, M.S. (1)